There is an Unmet Need for Treating Fungal SKIN Infections


Issues with Current Treatments

  • Low patient response rate around 30%
  • Undesirable side effects (oral antifungals)
  • Frequent recurrences and repetitive treatments


  • Strong IP position
  • Potential to prevent recurrences
  • Capital and time efficient development

DERmbiont's MICROBIAL Skin Therapeutics Platform

  • Dysbiosis is an unbalanced microbiome
  • Sequencing and characterizing disease stages
  • Building a bioinformatics platform for diagnostic and therapy prediction
  • We are only starting with fungal infections; our platform spans across a myriad of skin diseases.